Add Your Heading Text Here

In the Literature

Previous
Next

"The Pharmaceutical Sector" (authors), in The Business of Healthcare Innovation, 3rd Edition (Lawton Robert Burns, editor)

Prescription Drugs—List Price, Net Price, and the Rebate Caught in the Middle (Citation)

Changes in List Prices, Net Prices, and Discounts for Branded Drugs in the US, 2007-2018

Trends in Prices of Popular Brand-Name Prescription Drugs in the United States (Citation)

Trends in List Prices, Net Prices, and Discounts for Originator Biologics Facing Biosimilar Competition (Citation)

Biologics Are Natural Monopolies (Part 1): Why Biosimilars Do Not Create Effective Competition (Citation)

Biologics Are Not Natural Monopolies (Citation)

Financial Returns on R&D: Looking Back at History, Looking Forward to Adaptive Licensing (Co-Author)

Portfolio analysis and R&D decision making (Co-Author)

Measuring Prescription Drug Prices: A Primer on the CPI Prescription Drug Index

Estimation of Medicare Part D Spending on Insulin for Patients With Diabetes Using Negotiated Prices and a Defined Formulary (Citation)

The ACA Medicaid Rebate Rule Change: Impact on Pricing and Innovation (Citation)

Rebates in the Pharmaceutical Industry: Evidence from Medicines Sold in Retail Pharmacies in the U.S. (Citation; forthcoming)

Rebates in the Pharmaceutical Industry: Evidence from Medicines Sold in Retail Pharmacies in the U.S. (citation)

Health and Capital (Author)